HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease

被引：36

作者：

Brewer Jr. H.B. ^{[1
]}

机构：

[1] Department of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, Washington Hospital Center, Washington, DC 20010

来源：

Current Cardiology Reports | 2007年 / 9卷 / 6期

关键词：

Atorvastatin; Cholesteryl Ester Transfer Protein; Cholesterol Efflux; Acute Coronary Syndrome Patient; Torcetrapib;

D O I：

10.1007/BF02938393

中图分类号：

学科分类号：

摘要：

Developing new therapeutic approaches to treating residual cardiovascular risk of recurrent clinical events in statin-treated patients has been a major challenge for the cardiovascular field. Data from epidemiological evidence, animal models, and initial clinical trials indicate that increasing high-density lipoprotein (HDL) may be an effective new target for treating residual cardiovascular risk. Over the past several years, major advances have occurred in our understanding of HDL metabolism and of the important roles of the ABCA1 and ABCG1 transporters as well as the SR-BI receptor in cholesterol transport. Current approaches to HDL therapy include acute HDL infusion therapy in acute coronary syndrome patients and chronic oral HDL therapy in stable patients with cardiovascular disease. Definitive clinical trials will now be required to establish the safety and efficacy of increasing HDL in the treatment of patients with cardiovascular disease. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：486 / 492

页数：6

共 71 条

[31]

Brewer Jr H.B., Lux S.E., Ronan R., John K.M., Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex, Proc Natl Acad Sci USA, 69, pp. 1304-1308, (1972)

[32]

Hospattankar A.V., Brewer Jr H.B., Ronan R., Fairwell T., Amino acid sequence of human plasma apolipoprotein C-III from normolipidemic subjects, FEBS Lett, 197, pp. 67-73, (1986)

[33]

Williams D.L., Connelly M.A., Temel R.E., Et al., Scavenger receptor B1 and cholesterol trafficking, Curr Opin Lipidol, 10, pp. 329-339, (1999)

[34]

Duong M., Collins H.L., Jin W., Et al., Relative contribution of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages, Arterioscler Thromb Vasc Biol, 26, pp. 541-547, (2006)

[35]

Van Eck M., Bos S.T., Hildebrand R.B., Et al., Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development, Am J Pathol, 165, pp. 785-794, (2004)

[36]

Wang N., Lan D., Chen W., Et al., ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins, Proc Natl Acad Sci U S A, 31, pp. 9774-9779, (2004)

[37]

Kennedy M.A., Barrera G.C., Nakamura K., Et al., ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation, Cell Metab, 1, pp. 121-131, (2005)

[38]

Matsuura F., Wang N., Chen W., Et al., HDL from CETP-deficient subjects show enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway, J Clin Invest, 116, pp. 1435-1442, (2006)

[39]

Ranalletta M., Wang N., Han S., Et al., Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/ - bone marrow, Arterioscler Thromb Vasc Biol, 26, pp. 2308-2315, (2006)

[40]

Out R., Hoekstra M., Hildebrand R.B., Et al., Macrophage ABCG1 deletion disrupts lipid homeostasis in alveolar macrophages and moderately influences atherosclerotic lesion development in LDL receptor-deficient mice, Arterioscler Thromb Vasc Biol, 26, pp. 2295-2300, (2006)

← 1 2 3 4 5 6 7 8 →